Brain Mapping by Integrated Neurotechnologies for Disease Studies: Human Brain Aging Imaging Study

Brain Mapping by Integrated Neurotechnologies for Disease Studies: Human Brain Aging Imaging Study - Brain/Minds Aging Imaging Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017505

Enrollment

Registered

2015-09-01

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment, preclinical AD

Interventions

Brain Positron Imaging by intravenous administration of 11C-labeled amyloid PET diagnostic drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cognitive normal aged individual with CDR score 0 or MCI with CDR score 0.5 (memory box >= 0.5); amyloid PET positive cognitive normal is categorized as preclinical AD and those negative as normal aged. A study partner is available Age 60-90 MRI eligible Other dementing illness is not diagnosed. No past history of intracranial diseases.

Exclusion criteria

Exclusion criteria: No past history of major depression or bipolar disorder, schizophrenia, alcoholism or drug addiction. CT or MRI findings indicative of cerebrovascular disease or ischemic changes that are causative for cognitive disorders. Individuals who are continuously taking drugs affecting cognitive functions. Individuals with unstable disease states that may hamper continuation of the study Individuals who are participating in other clinical study including CDR, WMS-R, logical memory or MMSE upon enrollment

Design outcomes

Primary

Measure	Time frame
Volumetric differences in the hippocampus and other areas in cognitive normal and MCI Micro volumetric analysis of subregions of hippocampus and other medial temporal areas in cognitive normal and MCI Differences in cerebral blood flow using ASL in cognitive normal and MCI Differences in functional connectivity using rsfMRI in cognitive normal and MCI Differences in DTI parameters in cognitive normal and MCI Differences in brain volume in hippocampal and other areas in amyloid positive and negative individuals Differences in volume of subregions of hippocampus and other medial temporal areas in amyloid positive and negative individuals Differences in ASL and rsfMRI parameters in amyloid positive and negative individuals Differences in DTI parameters in amyloid positive and negative individuals	—

Measure

Time frame

Volumetric differences in the hippocampus and other areas in cognitive normal and MCI Micro volumetric analysis of subregions of hippocampus and other medial temporal areas in cognitive normal and MCI Differences in cerebral blood flow using ASL in cognitive normal and MCI Differences in functional connectivity using rsfMRI in cognitive normal and MCI Differences in DTI parameters in cognitive normal and MCI Differences in brain volume in hippocampal and other areas in amyloid positive and negative individuals Differences in volume of subregions of hippocampus and other medial temporal areas in amyloid positive and negative individuals Differences in ASL and rsfMRI parameters in amyloid positive and negative individuals Differences in DTI parameters in amyloid positive and negative individuals

—

Countries

Japan

Contacts

Public ContactKazushi Suzuki

The University of Tokyo Hospital Unit for Early and Exploratory Clinical Development

kazusuzuki-tky@umin.ac.jp0358415646

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026